JLC 062
Alternative Names: JLC-062Latest Information Update: 09 Sep 2025
At a glance
- Originator Jecho Laboratories
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Aug 2025 Preclinical trials in Unspecified in China (Parenteral) piror to August 2025 (Jecho laboratories pipeline; August 2025)